TESARO is an oncology-focused biopharmaceutical company. The company acquires, in-licenses and develops oncology product candidates. The company has in-licensed and is developing oncology-related product candidates, including rolapitant, niraparib, and the product candidates under its immuno-oncology platform. The company's existing products and product candidates are: Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting; Niraparib, an oral poly polymerase inhibitor for the treatment of ovarian or breast cancers; and Immuno-Oncology Platform, which is engaged in the discovery and development of antibodies for several immuno-oncology targets.
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.